Patents by Inventor Gerhard Höfle

Gerhard Höfle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
    Patent number: 8513280
    Abstract: The present invention is about the use of at least one epothilone or derivative thereof as an active ingredient for manufacturing a medicament for use in the treatment of disease(s) involving a neuronal connectivity defect.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: August 20, 2013
    Assignees: Institut National de la Sante et de la Recherche Medicale, Commissariat a l'Energie Atomique, Gesellschaft fur Biotechnologische Forschung mbH (GBF)
    Inventors: Annie Andrieux, Didier Job, Annie Schweitzer, Gerhard Höfle
  • Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
    Publication number: 20110118317
    Abstract: The present invention is about the use of at least one epothilone or derivative thereof as an active ingredient for manufacturing a medicament for use in the treatment of disease(s) involving a neuronal connectivity defect.
    Type: Application
    Filed: September 9, 2010
    Publication date: May 19, 2011
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Commissariat a l'Energie Atomique (CEA), Helmholtz Zentrum Fur Infektionsforschung GMBH (HZI)
    Inventors: Annie Andrieux, Didier Job, Annie Schweitzer, Gerhard Höfle
  • Elansolids, Novel Natural Metabolites of Flexibacter and Antibiotically Active Derivatives Thereof
    Publication number: 20110034528
    Abstract: The present invention describes Elansolids, a new class of novel anti-bacterial compounds of formula (I).
    Type: Application
    Filed: February 19, 2009
    Publication date: February 10, 2011
    Inventors: Klaus Gerth, Heinrich Steinmetz, Gerhard Höfle
  • Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
    Patent number: 7816370
    Abstract: The present invention is about the use of at least one epothilone or derivative thereof as an active ingredient for manufacturing a medicament for use in the treatment of disease(s) involving a neuronal connectivity defect, such as schizophrenia or autism.
    Type: Grant
    Filed: January 28, 2005
    Date of Patent: October 19, 2010
    Assignees: Institut National de la Sante et de la Recherche Medicale, Commissariat a l'Energie Atomique, Helmhaltz Zentrum Fur Infektions Forschung GmbH
    Inventors: Annie Andrieux, Didier Job, Annie Schweitzer, Gerhard Höfle
  • 2,3-olefinic epothilone derivatives
    Patent number: 6831090
    Abstract: The present invention relates to 2,3-position modified epothilone derivatives, methods of preparation of the derivatives, and intermediates therefor. The compounds of the invention as 16-membered macrolides having the general structure, which have microtubule-stabilizing effects and cytotoxic activity against rapidly proliferating cells, such as, tumor cells or other hyperproliferative cellular disease.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: December 14, 2004
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Robert M. Borzilleri, Gerhard Höfle, Thomas Leibold
  • Preparation of epothilone intermediates
    Patent number: 6593115
    Abstract: The present invention relates to a process for the preparation of intermediates useful in the synthesis of epothilone analogs by initially enzymatically degrading certain epothilone compounds to form ring-open structures containing a carboxyl group which is esterified, the hydroxyl groups on the moiety protected and the resulting compound oxidized by, e.g. ozone, to form a first intermediate. The first intermediate can be reacted with a triphenylphosphine adduct to yield a compound containing an ester group at position 1 which is subsequently hydrolyzed to form a second intermediate.
    Type: Grant
    Filed: March 19, 2001
    Date of Patent: July 15, 2003
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Gregory D. Vite, Soong-Hoon Kim, Gerhard Höfle
  • 2,3-olefinic epothilone derivatives
    Patent number: 6498257
    Abstract: The present invention relates to 2,3-position modified epothilone derivatives, methods of preparation of the derivatives, and intermediates therefor. The compounds of the invention as 16-membered macrolides having the general structure, which have microtubule-stabilizing effects and cytotoxic activity against rapidly proliferating cells, such as, tumor cells or other hyperproliferative cellular disease.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: December 24, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Robert M. Borzilleri, Gerhard Höfle, Thomas Leibold
  • 12,13-modified epothilone derivatives
    Patent number: 6399638
    Abstract: The present invention relates to 12,13-position modified epothilone derivatives, methods of preparation of the derivatives and intermediates therefor.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: June 4, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Soong-Hoon Kim, Gerhard Höfle
  • 12, 13-cyclopropane epothilone derivatives
    Patent number: 6380395
    Abstract: The present invention relates to 12,13-position modified epothilone derivatives, methods of preparation of the derivatives and intermediates therefor.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: April 30, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Gregory D. Vite, Soong-Hoon Kim, Gerhard Höfle
  • Epothilones with modified side chain
    Patent number: 6359140
    Abstract: Epothilones with a modified side chain and process for the preparation thereof are disclosed.
    Type: Grant
    Filed: August 17, 1999
    Date of Patent: March 19, 2002
    Assignee: Gesellschaft fuer Biotechnologische Forschung mbH (GBF)
    Inventors: Gerhard Höfle, Michael Sefkow